
Neurological Health
Better Biomarkers Could Help Us Treat Alzheimer’s
We need better molecular biomarkers to create targeted drugs
Howard M. Fillit is founding executive director and chief science officer at the Alzheimer's Drug Discovery Foundation in New York City. Credit: Nick Higgins
We need better molecular biomarkers to create targeted drugs
They're essential to coming up with better treatments, and a new initiative could provide them
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account